FDA Approves Drug for Advanced Thyroid Cancer
Progression-free survival with Lenvima was nearly five times longer compared to a placeboContinue Reading
Progression-free survival with Lenvima was nearly five times longer compared to a placeboContinue Reading
Progression-free survival with Lenvima was nearly five times longer compared to a placeboContinue Reading
Cigarette use thins key area for memory, thinking skills and languageContinue Reading
Early trials show promise of scans to help surgeons in the OR, or to track the effect of treatmentsContinue Reading
Recommended for use if radioactive iodine fails to stop progression
Continue Reading
Finding runs counter to current practice, researchers noteContinue Reading
But whether shared decision making results in better outcomes isn’t clear, study findsContinue Reading
Progression-free survival nearly five times longer in people receiving treatmentContinue Reading
Doctors’ claims that this is fueling increasing health costs unwarranted, expert saysContinue Reading
But cancer only affected about 2 percent of those in two-year follow-up periodContinue Reading
© 2021 WeeklyMD.com - All Rights Reserved.